Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study.

Emery, P., Fleischmann, R. M., Doyle, M. K., Strusberg, I., Durez, P., Nash, P., Amante, E., Churchill, M., Park, W., Pons-Estel, B., Xu, W., Xu, S., Wu, Z., & Hsia, E. C. (2013). Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function findings of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Arthritis Care & Research, 65(11), 1732-1742. https://doi.org/10.1002/acr.22072 (Original work published 2013)